EU drug regulator endorses changes to remdesivir marketing for COVID-19 use

New terms add that a patient can need ‘low- or high-flow oxygen or other non-invasive ventilation at start of treatment’

Tribune Web Desk

Updated At : 11:45 PM Dec 11, 2020 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Bengaluru, December 11

Europe’s medicines regulator on Friday recommended adopting changes to the terms of the conditional approval for Gilead’s remdesivir as a COVID-19 treatment in Europe, to make clear the conditions under which it can be used.

The new terms add that a patient could need “low- or high-flow oxygen or other non-invasive ventilation at start of treatment”, the agency said.

It is already indicated for use in patients aged 12 years and older with body weight at least 40 kg, and having pneumonia with a need for breathing support. Reuters

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles